相关实验视频

Updated: May 10, 2025

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
09:37

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Published on: August 1, 2018

14.9K

一个贝卡林向的ZHX2/MMP14轴减轻了肝硬化门户高血压

Hui Wang1, Jiawei Ma1, Jinghe Liu1

  • 1Emergency Department, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.

Current pharmaceutical biotechnology
|April 25, 2025
PubMed
概括

拜卡林 (BA) 通过上调ZHX2和减少MMP14来缓解循环门高血压 (CPH). 这项研究揭示了BABA.

关键词:
循环门高血压 循环门高血压贝卡林和贝卡林是最重要的.这是肝硬化.指和家庭盒 2;矩阵金属化酶 14

更多相关视频

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

19.3K
Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

6.2K

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
91